The research dossier
Follow the developments behind our reporting.
CSL (ASX:CSL) has reached new agreements with the Trump administration covering U.S. drug pricing and domestic manufacturing, adding another important development to the healthcare giant’s recent recovery story. CSL shares finished Tuesday modestly higher, but the bigger move has already happened. The…
CSL (ASX: CSL) shares jumped 5.7% to A$97.91 on Friday, its strongest one-day gain since February 2022. The move came as investors rotated back into ASX healthcare stocks after a painful year for the sector. CSL is still down almost 60% over…
The business behind the ticker
This page brings together our published coverage of ASX:CSL. A verified business profile has not yet been added.
Go to the source
Article source links are available within the timeline and in each original article. Reporting reflects the information available at its publication date.
This is a research coverage page, not a live exchange listing. Articles are matched to explicit exchange-and-ticker references in their titles and tags; coverage may not include every mention. Tickers and company details can change. Sector labels are our editorial research categories, not official exchange classifications.
